

15 May 2020

Renalytix AI plc  
("RenalytixAI", the "Company")

## Result of General Meeting

Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease, announces that at the general meeting of the Company held today the resolution to cancel the share premium account of the Company and to grant the Company the general authority to make market purchases of its own shares were passed. 99.99% (12,665,883 votes) of the votes were cast in favour of the resolution.

The Company is currently making the necessary court applications to enable it to proceed with the share buyback and will issue further updates at the appropriate time.

### *For further information, please contact:*

**Renalytix AI plc**  
James McCullough, CEO

[www.renalytixai.com](http://www.renalytixai.com)  
Via Walbrook PR

**Stifel (Nominated Adviser & Broker)**  
Alex Price / Jonathan Senior / Ben Maddison

**Tel: 020 7710 7600**

**N+1 Singer (Joint Broker)**  
Aubrey Powell / George Tzimas (Corporate Finance)  
Tom Salvesen (Corporate Broking)

**Tel: 020 7496 3000**

**Walbrook PR Limited**  
Paul McManus / Lianne Cawthorne

**Tel: 020 7933 8780** or [renalytix@walbrookpr.com](mailto:renalytix@walbrookpr.com)  
Mob: 07980 541 893 / 07584 391 303